CONTX Stock Overview
A medical technology software company, provides image analysis and imaging for medical systems in Asia, Europe, and America.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
ContextVision AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 4.84 |
| 52 Week High | NOK 9.20 |
| 52 Week Low | NOK 4.76 |
| Beta | 1.12 |
| 11 Month Change | -8.68% |
| 3 Month Change | -18.79% |
| 1 Year Change | -30.46% |
| 33 Year Change | -80.16% |
| 5 Year Change | -46.81% |
| Change since IPO | 30.81% |
Recent News & Updates
Recent updates
There May Be Some Bright Spots In ContextVision's (OB:CONTX) Earnings
Sep 02
ContextVision AB (publ)'s (OB:CONTX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio
Mar 11ContextVision's (OB:CONTX) Soft Earnings Are Actually Better Than They Appear
Feb 22ContextVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Feb 18Earnings Not Telling The Story For ContextVision AB (publ) (OB:CONTX)
Jan 26When Should You Buy ContextVision AB (publ) (OB:CONTX)?
Jun 22Is There Now An Opportunity In ContextVision AB (publ) (OB:CONTX)?
Jun 16Why ContextVision AB (publ) (OB:CONTX) Could Be Worth Watching
Mar 08Do ContextVision's (OB:CONTX) Earnings Warrant Your Attention?
Apr 19ContextVision AB (publ)'s (OB:CONTX) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Mar 13Here's What ContextVision AB (publ)'s (OB:CONTX) Shareholder Ownership Structure Looks Like
Feb 14
ContextVision (OB:CONTX) Shareholders Have Enjoyed A Whopping 664% Share Price Gain
Jan 19Are ContextVision's (OB:CONTX) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Dec 24Are Robust Financials Driving The Recent Rally In ContextVision AB (publ)'s (OB:COV) Stock?
Nov 28Shareholder Returns
| CONTX | NO Healthcare Services | NO Market | |
|---|---|---|---|
| 7D | -2.0% | -5.8% | -3.1% |
| 1Y | -30.5% | 19.0% | 0.8% |
Return vs Industry: CONTX underperformed the Norwegian Healthcare Services industry which returned 19% over the past year.
Return vs Market: CONTX underperformed the Norwegian Market which returned 0.8% over the past year.
Price Volatility
| CONTX volatility | |
|---|---|
| CONTX Average Weekly Movement | 4.8% |
| Healthcare Services Industry Average Movement | 5.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in NO Market | 10.6% |
| 10% least volatile stocks in NO Market | 2.6% |
Stable Share Price: CONTX has not had significant price volatility in the past 3 months compared to the Norwegian market.
Volatility Over Time: CONTX's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 41 | Gerald Potzsch | www.contextvision.com |
ContextVision AB (publ), a medical technology software company, provides image analysis and imaging for medical systems in Asia, Europe, and America. The company offers image enhancement software for 2D/3D/4D ultrasound, radiography, magnetic resonance imaging (MRI), and veterinary uses. Its products include Rivent that offers image enhancement and visualization solutions for ultrasound systems for women’s health, general imaging, cardiovascular, and point of care applications; Rivent Mobile, a 2D image enhancement product for handheld units; and Rivent 3D, an image enhancement solution for 3D ultrasound.
ContextVision AB (publ) Fundamentals Summary
| CONTX fundamental statistics | |
|---|---|
| Market cap | NOK 374.46m |
| Earnings (TTM) | NOK 26.12m |
| Revenue (TTM) | NOK 139.95m |
14.3x
P/E Ratio2.7x
P/S RatioIs CONTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CONTX income statement (TTM) | |
|---|---|
| Revenue | SEK 137.68m |
| Cost of Revenue | SEK 58.71m |
| Gross Profit | SEK 78.97m |
| Other Expenses | SEK 53.28m |
| Earnings | SEK 25.69m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 02, 2025
| Earnings per share (EPS) | 0.33 |
| Gross Margin | 57.36% |
| Net Profit Margin | 18.66% |
| Debt/Equity Ratio | 0% |
How did CONTX perform over the long term?
See historical performance and comparison